VYYRF - Voyageur Pharmaceuticals Ltd. Announces Signing LOI for Contract Manufacturing of Barium Radiographic Contrast Media with Alberta Veterinarian Laboratories Ltd.
(TheNewswire)
Calgary, Alberta - TheNewswire - November 30, 2020 - Voyageur PharmaceuticalsLtd. ( TSXV : VM ) USA ( OTC : VYYRF) (the "Company"or "Voyageur") announces that it hassigned a non-binding letter of intent with Alberta VeterinarianLaboratories Ltd ("AVL") to manufacture barium radiographic contrastmedia for Voyageur . Voyageur and AVL willnegotiate the terms of the definitive manufacturing contract and expect to have such contract in place in early 2021. AVL is an Alberta, family owned company that is led by Dr.Merle Olson. Dr. Olson is a member of the board of directors ofVoyageur. AVL is in the final stages of construction of their state ofthe art Calgary GoodManufacturing Practices (GMP) pharmaceuticalmanufacturing facility located in Calgary, Alberta. AVL manufacturesboth human and veterinarian pharmaceuticals products and operates aHealth Canada approved medical testing laboratory. The AVL plant isbeing tooled for GMP manufacturing of products under the AVL, Solvet,Rhino Clear and Voyageur brand products. AVL is building multiplemanufacturing lines that are planned to allocate production forVoyageur's radiographic barium contrast production. AVL currently hasbarium sulfate in their inventory and initial testing and productdevelopment is expected to begin in late January 2021, subject to theexecution of a definitive manufacturing contract. Voyageur's fivebarium contrast product lines are slated for production upon HealthCanada approvals that are expected in the first quarter of2021.
About AVL
Alberta Veterinary Laboratories Ltd. is apharmaceutical manufacturing company that specializes in qualityanimal health products and human health products. AVL creates manyinnovative products for thousands of farmers, vets, and pet owners,across Canada. AVL provides a Canadian manufacturing alternative to apopular anti-parasitic drug that saved cattle producers millions peryear. AVL expanded its portfolio of animal health products toencompass companion animals and other farm animals. AVL is aninnovative company that searches for new solutions to old problems.The industry leading Ivermectin Liquid for horses brought greatcomfort and ease to both owners and animals. All products are testedin Canada so they are suitable for the Canadian climate.
Voyageur Pharmaceuticals Ltd. is a Canadian publiccompany listed on the TSX Venture Exchange under the trading symbolVM. Voyageur is focused on the development of drugs related to theminerals barite and iodine as Active Pharmaceutical Ingredients("API") minerals. The near-term focus is developing bariumand iodine radiographic contrast products. Voyageur's goal is toinitially generate positive cash flow from operations using thirdparty pharmaceutical manufacturers. Ultimately, Voyageur will bebuilding the required infrastructure to become 100% self-sufficientwith all manufacturing of drugs and API minerals. Voyageur owns a 100%interest in three barium sulfate (barite) projects including its 100%owned Frances Creek barium sulfate property and also owns interests inan iodine, lithium and bromine heavy mineral brine project located inUtah, USA. Voyageur is moving forward with its business plan ofbecoming the only fully-integrated company in the radiographiccontrast medical field by controlling all primary input costs underthe slogan of: "From theEarth to the Bottle".
For further information, pleasecontact:
Ron Love, CFO, Cell: (403) 818-6086, RonL@Vpharma.ca
Brent Willis, CEO, Brent@Vpharma.ca
www.voyageurpharmaceuticals.ca
Reader Advisory
Neither the TSXVnor its Regulation Services Provider (as that term is defined in thepolicies of the TSXV) accepts responsibility for the adequacy oraccuracy of this news release.
Cautionary NoteRegarding Forward-Looking Statements
This news release contains certainstatements or disclosures relating to the Company that are based onthe expectations of its management as well as assumptions made by andinformation currently available to the Company which may constituteforward-looking statements or information ("forward-lookingstatements") under applicable securities laws. All suchstatements and disclosures, other than those of historical fact, whichaddress activities, events, outcomes, results or developments that theCompany anticipates may or will occur in the future (in whole or inpart) should be considered forward-looking statement and unduereliance should not be placed on any such statements. In some cases,forward-looking statements can be identified by the use of the words"will", "intends", "believes","expects", forecasts", "anticipates","plans" and similar expressions.
In particular, but without limitingthe foregoing, this news release contains forward-looking statementspertaining to the following: the entering into of a definitivemanufacturing contract with AVL; the feasibility and expectation ofthe Company to bring its mining assets into production; the experienceof management and directors of Voyageur and its pharmaceutical jointventure partner to execute on its business plan; the economics andrisks associated with its business plan; future operations andstrategies for development, sales and distribution of mineral andpharmaceutical products, including sales of barium contrast; theoutcome and timing of its preliminary economic assessment andpre-feasibility; expectations, including timing, related to revenuesand cash flow from operations; ability to successfully penetrateeither domestic or foreign pharmaceutical markets; the amount, qualityand cost of supply of active pharmaceutical ingredients for potentialpharmaceutical products; anticipated registrations with Health Canadaor similar foreign bodies for various pharmaceutical products theCompany plans to develop, produce and sell; and the ability of theCompany to attract investment capital to fund operations and capitalexpenditures.
The forward-looking statementscontained in this news release are made as of the date hereof and theCompany undertakes no obligations to update publicly or revise anyforward-looking statements, whether as a result of new information,future events or otherwise, unless so required by applicablesecurities laws.
Copyright (c) 2020 TheNewswire - All rights reserved.